Figure’s Helix 2.5 Pushes Humanoid Robots Toward Zero-Shot Generalization
Figure has released Helix 2.5, an AI model for its Figure 03 humanoid that lifted whole-task success in 30 unfamiliar…
Author: Marcus Chen
Based in Singapore, Marcus Chen specializes in the rapidly evolving fields of genomics, CRISPR technologies, and personalized diagnostics. With a background in bioinformatics and science journalism, he explores how genetic insights are transforming patient care and reshaping the diagnostic landscape. His investigative pieces often highlight the intersection of big data, AI, and next-generation sequencing in modern medicine.
Batten-1’s Phase 3 Submission Puts a Rare-Disease Trial Design Under the Microscope
THX Pharma, the Beyond Batten Disease Foundation and Biocodex have submitted regulatory applications to begin Batten-1-02, a Phase 3 study…
Argenx’s ALKIVIA Result Opens a New Therapeutic Front in Autoimmune Myositis
Argenx has reported positive Phase 3 results for VYVGART Hytrulo in autoimmune myositis, a heterogeneous group of rare inflammatory diseases…
Diagnostics Is Becoming a Distributed-Sampling Infrastructure Business
One of the more revealing healthcare developments of the last forty-eight hours did not come from a trial readout or…
MEDIPOST Advances Regenerative Orthopedics with Phase III Trial for Knee Osteoarthritis
The landscape of regenerative medicine reached a significant milestone this week as MEDIPOST Inc. announced the treatment of the first U.S.…
The Decentralized Intelligence Layer: How BioLayer Is Rewiring the Biotech Ecosystem
The global biotech ecosystem is currently living through a critical data paradox. Researchers have unprecedented access to high-resolution biological information…
Clinical-Trial Outsourcing Is Becoming a Biosecurity Diligence Problem
For years, the biopharma industry treated global clinical-trial geography as an execution question. Companies went where patient recruitment was faster,…
Oncology Is Turning Maintenance Therapy Into Strategy
Drug development stories are often told through breakthroughs at the moment of diagnosis: a new target, a sharper biomarker, a…
Regulatory Speed Is Becoming Its Own Biotech Asset Class
The renewed fight over the FDA’s priority-voucher pathway suggests that review time is turning from an administrative variable into a…
Beyond the Scale: What GLP-1 Drugs Are Really Doing to Your Body
Ozempic and Wegovy have become household names for weight loss, but a wave of new research reveals they are reshaping…
From Simulation to Clinic: How AI Is Rewriting the Rules of Drug Discovery
A 10,000-fold acceleration in molecular simulation, a hidden cancer-protein pocket missed by leading AI tools, and the first human trials…